Conditions

This post was originally published on this site Myriad Genetics has submitted the first part of a premarket approval application with the U.S. Food and Drug Administration for myChoice HRD CDx, a diagnostic test designed to identify ovarian cancer patients more likely to benefit from treatment with the PARP inhibitor Zejula (niraparib). Premarket approval is the FDA’s…

This post was originally published on this site Lynparza (olaparib) tablets have been approved by the European Commission as a standalone treatment for adults with a subset of locally advanced or metastatic breast cancer. The decision follows a recommendation by the Committee for Medicinal Products for Human Use (an arm of the European Medicines Agency), making…

This post was originally published on this site Some 87 buildings, landmarks, and businesses in the U.S. and Canada turned purple April 13 in an attempt to help raise awareness about sarcoidosis during Sarcoidosis Awareness Month. The initiative is called “Illuminate the Night: Shine a Light on Sarcoidosis,” and was begun by the nonprofit Foundation…

This post was originally published on this site Prostate cancer’s incidence and deadliness has declined or stabilized in much of the world in recent years, with the greatest decrease in risk evident in the U.S.,  a study reports. These findings were presented at the recent 2019 American Association for Cancer Research (AACR) Annual Meeting, which took…

This post was originally published on this site It’s probably not back. But if it is, it’ll kill me. Every six months, I travel to the Bay Area for tests to see if my triple-negative breast cancer is back. It’s nerve-wracking. I’ve already decided I won’t do chemo again; not because I hated chemo —…

This post was originally published on this site Vaccibody‘s VB10.NEO and Nektar Therapeutics‘ bempegaldesleukin (NKTR-214 or bempeg) work together to trigger a strong immune response against cancer cells, resulting in complete and durable tumor regression in a mouse model of colon cancer, a recent study says. The findings were featured in the poster, “Combination of neoantigen…

This post was originally published on this site The Japan Ministry of Health, Labour and Welfare (MHLW) has granted Sakigake Designation to valemetostat, an investigational treatment for adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The designation is given to promising therapies and aims to accelerate their development and review process, as well as reduce…

This post was originally published on this site Janssen Biotech is planning a new Phase 3 clinical trial to explore a combination of under-the-skin daratumumab plus Revlimid (lenalidomide) as a maintenance treatment for multiple myeloma patients who received an autologous stem cell transplant as front-line treatment. Specifically, the study is for patients who are positive for minimal…

This post was originally published on this site Women with invasive epithelial ovarian cancer have better survival rates at five years of diagnosis if they carry mutations in the BRCA1 and BRCA2 genes. However, this benefit decreases over 15 years of follow-up, according to a long-term study from Israel. The research, “Fifteen-year survival of invasive…

This post was originally published on this site Despite a United States Preventive Services Task Force (USPSTF) 2012 conclusion that routine tests for prostate cancer are unnecessary, a prominent oncologist believes such screenings should be encouraged. Vladimir Ioffe, MD, a radiation oncologist with 21st Century Oncology, said prostate-specific antigen (PSA) screenings ought to be recommended…